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Background: The epidemiologies of hepatitis C virus (HCV) and hepatitis B virus (HBV) infections in specific
populations in certain areas of China are poorly understood. A pilot survey of HCV/HBV infections was carried out in
villages in Kuancheng County, Heben Province, where injection of sodium benzoate or amphetamines using shared
needles has been a common practice. The aims of this study were to analyze the endemicity and characterize
HCV/HBV infections in this population.
Methods: Data on demographic characteristics and drug abuse were collected from individuals who signed informed
consent forms. Serum HCV antibody (anti-HCV), hepatitis B surface antigen (HBsAg), and hepatitis B core antibody
(anti-HBc) were measured in all participants. HCV RNA was measured in samples positive for anti-HCV using
real-time polymerase chain reaction.
Results: Among 852 participants from 11 villages, 49.9% had used sodium benzoate or amphetamine at least
once, by intravenous injection. The overall prevalence of anti-HCV, HCV RNA, anti-HBc, HBsAg, and HCV/HBV
co-infection was 37.1%, 26.6%, 67.7%, 10.7%, and 30.0%, respectively. Two-hundred-twenty-three of 227 (98.2%)
participants positive for HCV RNA were aged >40 years. Co-infection was related to sex, age, number of injections,
and time from first injection. The rate of spontaneous HCV RNA clearance was 28.2% (89/316), and was related to
the number of injections, time from first injection, and HBsAg positivity. However, HBsAg was related to the
anti-HBc signal/cut-off ratio rather than to the above parameters. Trend tests demonstrated that the prevalence
of anti-HCV, HCV RNA, and anti-HBc was related to the number of injections (P < 0.001), while HBsAg prevalence
was not (P = 0.347).
Conclusions: The prevalence of HCV and HBV infection is likely to be high among individuals older than 40 years
in areas of needle sharing, and one-time screening for HCV infection should be offered to these populations.
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The World Health Organization has estimated that around
150 million and >240 million people worldwide are chron-
ically infected with hepatitis C virus (HCV) and hepatitis B
virus (HBV), respectively, which are responsible for almost
1 million deaths every year [1,2]. Chronic HCV and HBV
infections are the most important causes of end-stage
liver diseases, including decompensated cirrhosis and
hepatocellular carcinoma [3]. Their early detection,
diagnosis, and treatment is the key to inhibiting or even
eradicating both these viruses. However, it is important to
understand the epidemiologies of HCV and HBV infec-
tions to allow the introduction of effective screening
programs.
Viral hepatitis is a major public health problem in
China. A nationwide cross-sectional seroepidemiological
study of hepatitis virus infections in 1992 showed an
overall prevalence of anti-HCV antibody of 3.2% (range
0.9–5.1%) among 66,975 subjects from 30 provinces [4].
Another seroepidemiological study using blood samples
and data from a nationwide survey of hepatitis B in 2006
found an overall prevalence of anti-HCV antibody of
0.43% among the general population aged 1–59 years [5],
indicating that around 5.6 million people were infected
with HCV. However, in addition to its status in the general
Chinese population, the HCV prevalence is higher in spe-
cific populations, such as intravenous drug users, patients
on maintenance hemodialysis, and paid blood donors.
Kuancheng County, Hebei Province lies in the North of
China. Sodium benzoate and amphetamines were com-
monly used here 20 years ago, for recreational purposes
and to alleviate fatigue. These drugs were often abused by
groups of guests at private functions, with the majority of
drug abusers being young farmers. We therefore conducted
a pilot survey to analyze the virological and epidemiological
characteristics of HCV in that region, and simultaneously




A total of 852 participants from 11 villages, randomly se-
lected from Kuancheng County, Hebei Province, were in-
cluded in the study. Participants were enrolled in the
study regardless of age and sex, and all participants gave
signed informed consent. The study protocol conformed
to the ethical guidelines of the 1975 Declaration of
Helsinki, was approved by the Ethics Committee at Peking
University People’s Hospital, and was performed according
to the guidelines of the International Conference on
Harmonization for Good Clinical Practice.
Data collection
A standardized questionnaire administered prospectively
by hepatologists was used to record demographic data
(including age and sex) and drug abuse. The data on
drug abuse included the probable number and type (so-
dium benzoate or amphetamine) of drugs used, and the
number of years from first drug use to December 2012.
Serum anti-HCV, HBsAg, and anti-HBc were measured
in all participants.
Virological detection
Elecsys anti-HCV II assay (Roche Diagnostics GmbH,
Penzberg, Germany) was used to detect anti-HCV [6] and
the results were expressed as signal/cut-off (S/CO) ratios.
The criteria for anti-HCV positivity and negativity were
based on the manufacturer’s instructions. An S/CO ≥1.0
was considered positive. HCV RNA was measured in sam-
ples positive for anti-HCV using the COBAS AmpliPrep/
COBAS TaqMan automated real-time polymerase chain
reaction platform (Roche Molecular Systems, Pleasanton,
CA, USA), with a lower limit of detection of 15 IU/mLBV markers at different ages.
Table 1 Characteristics of participants in relation to intravenous injection behavior
Factor Injection Non-injection Statistics P value
n = 425 n = 427
Age (years) 56.87 ± 9.23 45.96 ± 12.77 Z = −12.95 <0.001
Sex (male/female) 299/126 80/347 χ2 = 229.801 <0.001
Positive anti-HCV, n (%) 295 (69.4) 21 (4.9) χ2 = 379.699 <0.001
Positive HCV RNA, n (%) 222 (52.2) 5 (1.2) χ2 = 284.175 <0.001
Positive anti-HBc, n (%) 334 (78.6) 243 (56.9) χ2 = 45.798 <0.001
Positive HBsAg, n (%) 44 (10.4) 47 (11.0) χ2 = 0.096 0.757
Positive anti-HCV and anti-HBc, n (%) 242 (56.9) 14 (3.3) χ2 = 291.818 <0.001
Positive HCV RNA and HBsAg, n (%) 12 (2.8) 0 (0) χ2 = 12.229 <0.001
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HBsAg and anti-HBc levels were detected using Elecsys
HBsAg and anti-HBc assays (Roche Diagnostics), respect-
ively, according to the manufacturer’s instructions, where
an S/CO ratio ≥1.0 was positive for HBsAg and ≤1.0 was
positive for anti-HBc. We defined past co-infection with
HBV and HCV as seropositivity for both anti-HBc and
anti-HCV, and current co-infection as seropositivity for
both HBsAg and HCV RNA. Spontaneous clearance of
HCV was defined as positive for anti-HCV but negative
for HCV RNA in a patient without previous antiviral
treatment.
Statistical analysis
Continuous variables are presented as mean ± standard
deviation or median, and compared using Student’s t-
test, Kruskal–Wallis test, Mann–Whitney U test, or one-
way analysis of variance. Categorical variables are pre-
sented as number and percentage, and compared using
χ2 tests. The relationships between virological markers
and injection times were analyzed by the trend χ2 test.
Multiple logistic regression analysis was used to identify
factors related to HCV infection or spontaneous clear-
ance. All statistical analyses were performed using SPSS
16.0 (Chicago, IL, USA). Two-tailed P values < 0.05 were
considered significant. When performing multiple com-
parisons among the four groups, the level of significance
was adjusted to < 0.008.Table 2 Factors related to serum anti-HCV status and spontan
Anti-HCV
Positive (n = 316) Negative
Sex (male/female) 194/122 185/351
Age (years) 55.41 ± 9.41 49.04 ± 13
No. of injections (median) 25 0
Time from first injection (years, median) 26 0
Positive anti-HBc (n) 256 321
Positive HBsAg (n) 28 63Results
Study population and basic characteristics
Among the 852 participants from 11 villages, 379 (44.5%)
were men. The mean age was 45.16 ± 11.06 years (range:
12–86 years), with 41, 79, 235, 272, 179, and 46 participants
aged <30, 30–39, 40–49, 50–59, 60–69, and ≥70 years,
respectively. Four-hundred-twenty-five (49.9%) partici-
pants had used sodium benzoate or amphetamine at
least once, administered by intravenous injection with
needle sharing, and 147, 141, and 137 people had
injected 1–10, 10–29, and ≥30 times, respectively. The
number of injection times was related to the time from
first injection to the survey (rs = 0.911, P < 0.001). More
men than women had injected intravenously (70.4% vs.
29.6%, χ2 = 229.801, P < 0.001), and people aged ≥40 years
accounted for 99.5% of all participants (Figure 1). Com-
pared with participants who had not injected intraven-
ously, those who had injected were older, more likely to be
male, and had a higher prevalence of anti-HCV, HCV
RNA, and anti-HBc. However, there was no significant dif-
ference in the prevalence of HBsAg between the two
groups (Table 1).
HCV infection in an area of epidemic needle sharing
The overall prevalence of anti-HCV was 37.1% (316/852).
An S/CO >10 was seen in 306 of 316 (96.8%) people who
were positive for anti-HCV. HCV RNA was detected in
227 of 852 (26.6%) participants, and thus in 71.8% of thoseeous HCV clearance
P value Spontaneous HCV clearance P value
(n = 536) No (n = 227) Yes (n = 89)
<0.001 147/80 47/42 0.05
.36 <0.001 56.18 ± 9.16 53.44 ± 9.82 0.20
<0.001 25 20 0.003
<0.001 27 24 0.001
<0.001 182 74 0.545
0.187 12 16 <0.001
Figure 2 Percentages of various positive HCV/HBV markers at different injection times. (Trend tests: P < 0.001 between anti-HCV, HCV RNA, and
anti-HBc and number of injections, respectively; P = 0.347 between HBsAg and injection times).
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serum anti-HCV status was related to sex, age, number of
injection times, time from first injection, and anti-HBc
positivity. Multiple regression analysis showed that
anti-HCV positivity correlated significantly with male
sex (odds ratio (OR) 1.218, 95% confidence interval
(CI) 1.103–1.461, P < 0.001), older age (OR 1.922, 95%
CI 1.898–1.947, P < 0.001) and more injections (OR
1.741, 95% CI 1.566–1.936, P < 0.001). The rate of
spontaneous HCV RNA clearance was 28.2% (89/316),
which was related to number of injections, time from
first injection, and HBsAg positivity. Only HBsAg positiv-
ity correlated significantly with spontaneous HCV RNA
clearance by multiple logistic regression analysis (OR
4.640, 95% CI 2.049–10.506, P < 0.001). HCV prevalence
was significantly higher in people aged ≥40 years (306/
732; 41.8%) compared with those <40 years (10/120; 8.3%)
(χ2 = 49.498, P < 0.001) (Figure 1). Two-hundred-twenty-
three of the 227 (98.2%) participants who were positive for
HCV RNA were aged >40 years. The relationship between
virological markers and number of injections is shown in
Figure 2. Trend tests demonstrated that the prevalence of
anti-HCV and HCV RNA were related to the number of
injections (P < 0.001).Table 3 Factors related to serum anti-HBc and HBsAg status
Anti-HBc
Positive (n = 577) Negative (n
Sex (male/female) 277/300 102/173
Age (years) 53.31 ± 11.05 47.40 ± 14.12
No. of injections (median) 5 0
Time from first injection (years, median) 22 0
Anti-HBc S/CO ratioHBV infection in an area of epidemic needle sharing
The overall prevalence of anti-HBc and HBsAg was 67.7%
(577/852) and 10.7% (91/852), respectively. HBsAg was
detected in 87/577 (15.1%) of those who were positive for
anti-HBc. Serum anti-HBc status was related to sex, age,
number of injections, and duration from first injection.
HBsAg was not related to the above parameters, but was
related to anti-HBc S/CO ratio (Table 3). The prevalence
of anti-HBc and HBsAg according to the number of injec-
tions are shown in Figure 2. Trend tests demonstrated that
the prevalence of anti-HBc was related to the number of
injections (P < 0.001), while the prevalence of HBsAg was
not (P = 0.347).
HBV/HCV co-infection in an area of epidemic needle
sharing
The participants were divided into four groups: anti-
HCV and anti-HBc positive (group 1); anti-HCV positive
(group 2); anti-HBc positive (group 3); and anti-HCV and
anti-HBc negative (group 4). A total of 30.0% of partici-
pants were group 1. Compared with participants who were
positive for anti-HCV alone (group 2), those with HBV/
HCV co-infection (group 1) had a lower anti-HBc S/CO
ratio (P < 0.001), but sex, age, number of injections, andP value HBsAg P value
= 275) Positive (n = 91) Negative (n = 761)
0.003 45/46 334/427 0.313
<0.001 50.34 ± 9.88 51.53 ± 12.70 0.39
<0.001 0 1 0.376
<0.001 0 19 0.473
0.006 0.096 <0.001
Table 4 Factors related to HCV and HBV infections assessed by anti-HCV and anti-HBV










(n = 256) (n = 60) (n = 321) (n = 215)
Sex (male/female) 159/97 35/25 118/203 67/148 χ2 = 60.067 <0.001 0.589 <0.001 <0.001
Age (years) 56.00 ± 9.20 52.87 ± 9.95 51.15 ± 11.91 45.88 ± 14.74 F = 28.732 <0.001 0.157 <0.001 <0.001
No. of injections (median) 25 20 0 0 χ2 = 554.047 <0.001 0.033 <0.001 <0.001
Time from first injection
(years, median)
26 25.5 0 0 χ2 = 315.472 <0.001 0.441 <0.001 <0.001
Anti-HBc S/CO ratio 0.006 1.63 0.006 1.80 χ2 = 589.908 <0.001 < 0.001 0.319 <0.001
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contrast, there was no significant difference in anti-HBc S/
CO ratio between those in group 1 and those positive
for anti-HBc alone (group 3). All five factors differed
significantly between groups 1 and 4 (Table 4). The
four groups were divided on the basis of HCV RNA
and HBsAg. Comparing group 1 with the other groups,
there were significant differences in the number of in-
jections and time from first injection between groups 1
and 3, and in the number of injections, time from first
injection to present, and anti-HBc S/CO ratio between
groups 1 and 4 (Table 5).
Discussion
National surveys in 1992 and 2006 showed a decline in the
prevalence of anti-HCV from 3.2% to 0.43% in the general
population in China, mainly as a result of the stringent ad-
ministration and screening of blood donors and blood
products. However, about 45% of HCV-infected people
were in high-risk groups, such as intravenous drug users,
patients undergoing maintenance hemodialysis, and paid
blood donors [7]. The pooled prevalence of anti-HCV
among intravenous drug users in China was 61.4% [8].
Mother-to-child transmission is a major cause of HBV in-
fection in China, and other high-risk groups include
hemodialysis patients, HIV-positive patients, and unpro-
tected sexual exposure [9]. However, the impact of multiple
injections on HBV infection, and the characterization ofTable 5 Factors related to HCV and HBV infections assessed b
HCV RNA and HBsAg
Both positive (1) Positive
HCV RNA (2)
(n = 12) (n = 215)
Sex (male/female) 9/3 138/77
Age (years) 57.17 ± 7.88 56.13 ± 9.23
No. of injections (median) 27.5 25
Time from first injection (years, median) 29.5 27
Anti-HBc S/CO ratio 0.006 0.10HCV and HBV co-infection following intravenous injec-
tion, are unclear.
The current survey found overall prevalence of anti-
HCV and HCV RNA of 37.1% and 26.6%, respectively,
which were higher than in the general population. Most
people who were positive for anti-HCV were men older
than 40 years. More injections and a longer duration from
first injection were associated with a higher prevalence of
anti-HCV and HCV RNA, and decreased spontaneous
clearance of HCV. These data suggest that intravenous
injection was the most important transmission route of
HCV in Kuancheng County.
Family clustering of HBV infection occurs in China as
a result of mother-to-child transmission. The rate of
progression from acute to chronic HBV infection is re-
lated to age at infection, being as high as 90% for peri-
natally acquired infections but around 5% for adults
[10]. The weighted prevalence of HBsAg and anti-HBc
in the Chinese population aged 20–59 years was 8.97%
and 43.9%, respectively [11]. The equivalent prevalence
in the current study was 10.7% and 67.7%, respectively,
and HBsAg was detected in 15.1% of those who were
positive for anti-HBc, suggesting that most of them ac-
quired HBV infection during adulthood. Anti-HBc, ra-
ther than HBsAg status, was related to sex, age, number
of injections, and time from first injection, further sug-
gesting that most people had acquired HBV infection








(n = 79) (n = 546)
36/43 196/350 χ2 = 54.658 <0.001 0.547 0.057 0.011
49.30 ± 9.78 49.72 ± 13.41 F = 16.129 <0.001 0.998 0.036 0.042
0 0 χ2 = 410.937 <0.001 0.902 <0.001 <0.001
0 0 χ2 = 247.583 <0.001 0.515 <0.001 <0.001
0.006 0.28 χ2 = 105.000 <0.001 0.014 0.923 <0.001
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prevalence of both anti-HCV and anti-HBc positivity in
the current study was 30.0%, while that of both HCV
RNA and HBsAg positivity was 1.4%. Moreover, spon-
taneous clearance of HCV was associated with HBsAg
(not anti-HBc), in agreement with previous reports
[12,13]. Serum HBsAg levels are considered to be a sur-
rogate marker of viral activity in infected hepatocytes,
and in part represent the interaction between HBV and
the host immune response. However, the role of HBsAg
in HCV clearance is unclear, but may be influenced by
some aspects of the viral life cycle or may involve the ac-
tivation of innate immunity by HBsAg [13,14].
There were some limitations to the present study. It was
not conducted by random cluster sampling. Furthermore,
we had no data on occult HBV infection, defined as the
presence of HBV DNA in the serum or liver of patients
with negative HBsAg test results. Despite these limitations,
the survey demonstrated a high prevalence of HCV and
HBV infections (especially HCV infection) in areas where
needle sharing was common, such as Kuancheng County.
In contrast to the epidemiology of HBV infection, HCV
infection in mainland China shows no family aggregation,
but does demonstrate aggregations in regional, ethnic, or
specific populations associated with particular life habits
or religious customs. Regional aggregation is more pro-
nounced in rural areas and populations, which have a
higher prevalence of anti-HCV than in the general popula-
tion. Surveys of HCV epidemiology should thus take these
factors into account. Although populations at high risk of
HCV infection have been paid increasing attention in clin-
ical practice since 1993, no effective screening has been
performed in high-risk areas. In the United States, around
75% of patients with HCV infection were born between
1945 and 1965, with a peak prevalence of 4.3% [15,16],
and the US Preventive Services Task Force recommends
offering one-time screening for HCV infection to this co-
hort [17]. In the present study, we found that injection of
sodium benzoate largely occurred between the 1970s and
1990s, and 98.2% of patients positive for HCV RNA were
over 40 years old. In contrast, the 2006 national survey
showed no significant difference in the prevalence of HCV
infection among different age groups in the general popu-
lation, though the highest prevalence of 0.83% was found
in persons aged 50–55 years [5]. However, we suggest that
one-time screening for HCV infection should be offered
to people in high-risk age groups in high-risk areas, and
routine screening should be performed in high-risk
populations.
Conclusion
Prevalence of HCV, HBV and HCV/HBV co-infection is
likely to be high in areas of China where needle sharing
has been a common behavior, with intravenous injectionbeing an important causative factor for chronic viral hepa-
titis, especially hepatitis C. More attention should be paid
to routine screening for HCV and HBV in high-risk areas.
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